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Innovations
Astex, Structural Genomix, and Syrrx
I Can See Clearly Now:
Structural Biology and Drug Discovery
tire [pharmaceutical] industry values the last six months, we have become
a drug discovery company.”and leveraging those structures as
In contrast, Astex, based in Cam-starting points for structure-based
bridge, United Kingdom, distin-design programs. The idea is that
guishes itself from Syrrx and Struc-when we have unique access to
In 1999, after a decade that had
spawned a glut of companies im-
mersed in high-throughput screen-
ing techniques for drug hunting,
three pioneering biotechnology ven-
tures emerged with a fresh ap- tural Genomix because it was neverstructure, we are going to be more
proach. What set Syrrx, Structural part of the structural genomics ini-efficient than the rest of the industry
Genomix, and Astex apart from the tiative. Harren Jhoti, cofounder andon those targets.” “What has hap-
crowd was their idea to harness the CSO of Astex, emphasizes this fact,pened is that people with more phar-
powerful technology of structural “From day 1 we were focused onmaceutical experience were added
biology in a whole new way to chemistry. We never had a businessto the management team and [they]
change the rules drug discovery. model that said that we would solvehave been changing the company
Since 1840, when the first protein crystal structures of lots of proteinand focusing on the downstream
crystal structure was documented which we would then commercializetransformation of the structural in-
by F.L. Hunfield, who undertook the to pharmaceutical companies.” Jhotiformation into drug leads,” contin-
extraordinary feat of uncovering the had accumulated 10 years of experi-ues Keith Wilson, Syrrx’s VP of Dis-
structure of earthworm hemoglobin, ence in structural biology as head ofcovery Technologies and Structural
the field of protein crystallography structural biology and bioinformat-
had progressed to a point where it ics with Glaxo Wellcome when he
was available for use by researchers set up Astex with Tom Blundell and
“We are anticipating mostworldwide. However, in general it re- Chris Abell from the University of
Cambridge, UK. “The idea and keymained confined to the realm of an drug discovery to be
academic community of structural driving force behind the companystructure-driven in the
biologists who used this then cumber- was to think about X-ray crystallog-
next five to ten years.some and time-consuming method to raphy in a different way and specifi-
cally to develop high-throughputcreate beautiful detailed images of Clearly, [stucture-based]
proteins to gain an understanding, X-ray crystallography so that weknowledge-driven ap-
from looking at the structure itself, could use structure-based design
proaches are comingof how proteins form and how form for screening technology as well as
for lead [drug] optimization. The ini-relates to function. Syrrx, Structural back into favor now be-
Genomix, and Astex have revolu- tial idea therefore hasn’t changedcause the lack of knowl-
tionized structural biology into a significantly over the last three
edge-driven approachessleek tool and are now neck-and- years.” In the nineties, the trend
among pharmaceutical companiesneck in competing to put the first have not delivered.”
structure-based designed drug in was to identify potential drug leads–Harren Jhoti, cofounderclinical trials. or “hits” by brute force: if a chemist
and CSO of AstexStructure-Based Drug Design: could make enough compounds and
Driven by Knowledge screen enough targets, it was likely
San Diego-based enterprises Struc- that they would find some desirable
Chemistry. Structural Genomix hadtural Genomix and Syrrx both began activity. But Jhoti states that this is
a similar wake-up call after begin-with a plan to automate the struc- not an effective method for drug dis-
ning with a plan to establish a data-tural biology process to rapidly crys- covery, “We are anticipating most
base of the structures of medicallytallize proteins on a massive scale, drug discovery to be structure-
relevant proteins and to sell accessbut soon realized that this alone was driven in the next five to ten years.
to that information. “That modelnot a marketable tool, and expanded Clearly, [stucture-based] knowledge-
changed in May 2001 when Struc-their horizons to utilize the crystal driven approaches are coming back
tural Genomix purchased Prospectstructures that they were creating into favor now because the lack of
Genomics, an in silico drug discov-for drug discovery. Ned David, who knowledge-driven approaches have
ery company of which I was one ofcofounded Syrrx with Peter Schultz not delivered.”
the cofounders,” says Stephen Bur-and Raymond Stevens, both cur- Protein Crystals by Robotics
ley, CSO and Senior VP of Research.rently at Scripps, explains, “Over the All three companies have adapted
“By combining that with the high-years, we have figured out that the X-ray crystallography for the fast-
throughput structure determinationbusiness we should be in is getting paced biotech world in similar ways,
platform and medicinal chemistryunique access to [protein] struc- with some unique differences. In this
trio’s race to market the first struc-tures which are targets that the en- program that we have built up over
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ture-based rationally designed drug, tracted the attention of pharmaceu- they are sent to the company’s pro-
prietary third-generation beamlineit is these differences which may tical groups including Hoffman-La
Roche, Sanyko Co. LTD, Pharmacia,prove the cornerstone to success synchrotron at the Advanced Pho-
ton Source in Chicago. “This is argu-and subsequent longevity. Syrrx and Cubist Pharmaceuticals, all of
whom have formed collaborative al-prides itself on its gene-to-structure ably the best protein crystallography
beamline in the world, and it hasapproach and has highly automated liances with Syrrx. Two of Syrrx’s
most promising in-house projectshigh-throughput crystallography. Us- been tailored to our needs,” Stephen
Burley proudly explains. “In laying a parallel fermentation system involve dipeptidyl peptidase IV
(DPP-IV) and histone deacetylasesand the Sonic Hedgehog robot, terms, the reason that this photon
source is so effective is that the elec-Syrrx can make and purify 100 pro- (HDACs). The group has solved
novel structures for both humanteins in 5 hr. The purified protein is tron beam is extremely small, and
that means that all of the X-ray pho-then moved to the Agincourt crystal- DPP-IV and a human HDAC and is
currently screening for specific in-lization robot, which was reengi- tons end up in a very narrow beam,
and you can work with small crys-neered from an automobile factory hibitors of both enzymes. DPP-IV is
an amino peptidase that cleaves theby Bob Downs from the Genomics tals.” Crystals, frozen in liquid nitro-
gen, are shipped from San Diego toInstitute of the Novartis Research N terminus of incretins (peptide hor-
mones that are released from the gutFoundation. Agincourt can accu- Chicago daily, and diffraction exper-
iments are conducted at the beam-rately generate 100 nl crystallization in response to nutrients that en-
hance glucose-stimulated insulindroplets, enabling the structural in- line to quickly generate complete de
novo structures using technologyformation to be obtained from very secretion). Inhibitors of DPP-IV ac-
tivity would result in enhanced incre-small amounts of protein. In fact, developed by Wayne Hendrickson
(Columbia University), one of Struc-Keith Wilson notes that this is a nota- tin activity and may represent a
novel treatment for type II diabetes.ble triumph for Syrrx, and patent fil- tural Genomix’s cofounders. This
photon source also allows for pre-ings are in process for the enabling Inhibition of HDAC activity has strong
therapeutic potential to inhibit therobotics: “It depends on the protein, cise cocrystal structure determina-
tion that is protein with inhibitor li-but the small volumes are crucial. No onset and progression of cancer,
since HDAC activity is associatedone can explain this, but the crystals gand bound, which is crucial for
Structural Genomix’s recently devel-grow faster in the small droplets, with chromatin remodeling and de-
creased rates of transcription.sometimes in a few hours or a day oped highly integrated medicinal
chemistry, inhibitor activity screen-instead of a few days to a week.” Like Syrrx, Structural Genomix
has a considerable focus on tar-Remarkably, the integrity of the ing, and computational chemistry
process for drug development, whichcrystals that develop in the small geting protein families, such as ki-
nases, and is working on targets rel-droplets is also higher than for crys- ultimately directly looks at how an
inhibitor is bound in the active sitetals developed with regular method- evant to oncology, cardiovascular
disease, and immune dysfunctionsology, and they diffract X-rays better of a protein. The process begins
once the target protein structure istoo, allowing for high-quality im- such as asthma and inflammation.
Similarly, Structural Genomix has aaging. With a crystal structure in known, and researchers use a com-
bination of real libraries (one ofhand, medicinal chemists can be broad base of corporate alliances,
including technology partnershipsmore efficient and can use this infor- which is focused around particular
pharmacophores; another containsmation to make a hundred specific with Aventis, Millennium, and Boeh-
ringer Ingelheim Pharmaceuticalscompounds rather than thousands. drug-like fragments) and virtual com-
pound libraries to look for com-At this stage, screens for drug leads and drug discovery partnerships
with Asahi and Anadys. Interest-using rational drug design are car- pounds that bind to target proteins.
Compounds that are found to bindried out both in vitro and in silico. ingly, the company has established
novel research partnerships withLike most other companies, Syrrx to the target either in vitro or in silico
are confirmed with actual enzymeis striving to develop drugs that tar- The Cystic Fibrosis Foundation to
study the structure of CFTR (cysticget proteases and kinases and, in assays, and then the crystal struc-
ture of the target protein with thefact, is specifically targeting pro- fibrosis transmembrane conductance
regulator), the Hereditary Diseaseteins that already have inhibitors in successful inhibitor bound to its ac-
tive site is obtained. By directly ob-clinical trials. “The Syrrx philosophy Foundation, where they are working
on the Huntington protein, and theis to take this target protein and use serving how compounds bind to
their target and by using extensivethe structural information generated NIH, with which they are collaborat-
ing with eight other research centersin-house to produce compounds computational analysis, particular
inhibitors are then chosen as chemi-that can compete with the drug un- in the public Structural Genomics
Research Consortium.der trial as soon as possible,” ex- cal scaffolds and will be repeatedly
modified by medicinal chemists toplains Keith Wilson. “The key to our Structural Genomix has adopted
a modular approach to their highlysuccess will be whether our inhibi- generate a more potent drug. “To
give you an idea of how rapidly wetors are different, at least as good, automated protein crystallization
technology to enable the expres-if not better, and that they are going can proceed through this cycle, we
have repeatedly documented turn-to come fast, and this is facilitated sion, purification, and crystallization
conditions to be precisely controlledby being able to see how everything around times of less than one week
from assay to cocrystallization data,”fits together (protein and com- for each particular protein family of
interest. As protein crystals emerge,pound).” Syrrx’s technology has at- comments Stephen Burley. He fur-
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ther explains, “We are doing two tored by biophysical methods such plied our structural biology capabili-
ties to solve the crystal structure [ofthings to ensure that what we are as crystallography and NMR. “We
felt that crystallography should givetaking through lead optimization these enzymes], which was a very
difficult task—many people hadhad the highest chance of success. an advantage over NMR because it
gives you much more accurate infor-We are examining selectivity by con- been trying to solve these structures
for about 15 years. At the end ofducting cocrystallography with re- mation about the binding of small
molecules,” says Jhoti. “In a nut-lated targets to understand how 2001, we announced that we had
solved the first human P450 struc-these compounds are binding to the shell, what Astex has been doing for
the last three to four years is usingoff-targets, while increasing the po- ture, and the second was solved in
2002. Last year we disclosed whichtency of binding to the target itself. crystallography in a high-throughput
way to screen fragment libraries andThe other issue is whether the com- isoforms they were as well (3A4 and
2C9). Those are two of the four keypound that we are making is going look for binding of these fragments
to a target. We have really pioneeredto be useful as a drug, so we are drug metabolizing proteins.” Astex
is now using this structural informa-doing cell-based assays and prelim- this area and are quite different from
the other guys as far as we can tell, ininary ADMETs.” (ADMETs are ad- tion to optimize drugs to ensure that
metabolic turnover is reduced. How-sorption, distribution, metabolism, that they have not really been using
their high-throughput crystallogra-excretion, and toxicology analyses.) ever, Jhoti warns, “There is a bal-
ance here; you don’t want to com-Astex’s research program has a phy in the same way.”
Astex is validating its expertise bydifferent flavor because of its con- pletely obliterate the interaction
because you want there to be somesistently strong bias toward chemis- using well-characterized target pro-
teins. Jhoti clarifies, “We never fig-try. The company’s core focus is on turnover.”
Despite the differences in their ini-fragment-based drug discovery, us- ured that there was a huge need for
new target proteins; in fact the in-ing 24/7 high-throughput X-ray co- tial perspectives, scientific strate-
gies, and technologies, Astex, Syrrx,crystallography to identify critical dustry is target rich and lead poor,
and there are plenty of good targetsfragments with trademarked tech- and Structural Genomix all obvi-
ously share a common vision: thatnologies known as Autosolve and out there. The problem has been
coming up with good lead com-Pyramid. “In the nineties, we all ob- structure-based drug design will
have a strong impact on the future ofserved that there were fundamental pounds. So many of our targets are
[also] on the [target] lists of manyproblems with combinatorial chem- drug discovery. But does structure-
based drug design hold the key toistry type of approaches, where pharmaceutical companies, but we
think that our technology shouldcompounds were being synthesized the future of drug discovery? Con-
sidering this prospect, Jhoti, of As-and screened at tremendous rates,” give us an advantage in coming up
with lead drugs.” Since both thecomments Harren Jhoti. “But if you tex, is exuberant. He exclaims, “Of
course! I left a good position atactually looked at the size of the structures and biological activities
of these target proteins have beencompounds, they were generally in- Glaxo Wellcome to set up Astex, and
we are all absolutely committed tocreasing in size, and so the actual well defined, the researchers can
make well-informed decisions aboutmolecular weight in a pharmaceuti- this new approach. For example,
several of our senior managementcal company’s collection was in- where they would like the fragments
to bind to have a disruptive effectcreasing as the years went on.” team have come from big pharma
companies, such as Robin Carr, VPLarge compounds often become on the function of the protein. “We
have potent lead compounds in theproblematic at the later stages of de- of Drug Discovery, who was head of
lead discovery and high-throughputvelopment, because they are less nanomolar range that are active in
cells, so we have shown that we canlikely to make it into cells and there- screening for Glaxo Wellcome. This
exemplifies their belief in the struc-fore have a lesser chance of being take millimolar hits and grow them
using structural knowledge into na-a successful drug. Consequently, ture-based approach over conven-
tional methods for drug discovery.”Astex decided to take a Lego-like nomolar lead compounds. We are
also looking at proteins that are lessapproach to drug design and start When posed the same question,
Burley, of Structural Genomix, is posi-lead generation using very small characterized, and we may think
about looking at fragment screeningcompounds indeed. Jhoti elabo- tive: “Structure-based approaches to
drug discovery represent the newestrates, “If we could use fragments to in a different way,” but it is too early
to discuss this at this time, contin-start our chemistry, we would be technology to come into the arena.
Five years ago, everyone was talkingmuch smarter because we would ues Jhoti.
A project unique to Astex is theironly add on to the initial fragment about the potential impact of high-
throughput screening, and what wewhat was necessary.” The problem cytochrome P450 study, in which it
collaborates with Astrazeneca, Aven-Astex had to overcome was identi- have seen is that high-throughput
screening has been very effective infying the initial target binding frag- tis, and Mitsubishi Pharma. “A lot of
drugs fail due to metabolic prob-ments, because they are inherently some contexts and not as effective
in others, and that overall it did notvery weakly binding entities with a lems, or they get turned over by
these cytochrome P450 enzymes,size of less than 150 MW, and they represent the panacea that some
people thought that it was going tooften bind with very low potency and that can produce toxic products
that give you problems with side ef-(with high hundreds of a micromolar be. By the same token, it would be
unrealistic to expect that structure-to a millimolar affinity). However, this fects or drug-drug interactions,”
says Jhoti, explaining, “We have ap-binding interaction can be moni- based techniques and strategies are
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going to solve all of the problems in
drug discovery, but I don’t think that
there is any substitute for a direct
look at how an inhibitor is binding
to a target, and more importantly,
how the inhibitor may interact with
other potential targets in the body,
some of which you may want to in-
hibit and others which would obvi-
ously be very deleterious for the pa-
tients.” Wilson and David from Syrrx
agree: “Other things have come and
gone, and there has certainly been
hype about structural information
and its utility, but I don’t think that
structure-based drug design is the
pinnacle,” Wilson responds. “How-
ever, I do think that it will rise above
lots of other technologies in terms
of utility, and I think it may have al-
ready.” If the world of drug discovery
is likened to a chessboard, then Da-
vid believes that structure-based
drug design is analogous to the
queen. “It’s not the king because
you don’t need the king to play, but
the queen allows you to move in any
direction,” he says. “You can keep
playing the game without the queen,
but you just play a lot worse.”
The power of clear, precise visual-
ization of protein targets with X-ray
crystallography will undoubtedly
mold and reshape the conventional
strategies of the drug hunters of to-
morrow. For Syrrx, Structural Ge-
nomix, and Astex, their impact on
the global biotech community will be
marked by the unveiling of the first
successful drug designed with struc-
ture-based technologies. None of
these young companies have com-
pounds in clinical trials at this time,
but the race to the finish line has
begun.
Chemistry & Biology invites your
comments on this topic. Please
write to the editors at chembiol@
cell.com.
Vicki Mountain is the Assistant Editor of
Chemistry & Biology (vmountain@cell.com).
